Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jan 22:13:53-60.
doi: 10.2147/JIR.S215196. eCollection 2020.

Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis

Vidhatha Reddy  1 , Eric J Yang  2 , Bridget Myers  1 , Wilson Liao  1
Affiliations
Review

Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis

Vidhatha Reddy et al. J Inflamm Res. .

Abstract

Risankizumab-rzaa (Skyrizi®; AbbVie) is a humanized IgG monoclonal antibody directed against interleukin-23p19 (IL-23p19) indicated for the treatment of moderate-to-severe psoriasis in adults who are candidates for systemic therapy or phototherapy. Four pivotal Phase III trials: UltIMMa-1, UltIMMa-2, IMMhance, and IMMvent have demonstrated efficacy and safety in patients with moderate-to-severe plaque psoriasis. This review highlights important findings from these and other clinical trials that have evaluated risankizumab. In addition, we discuss the mechanism of action, pharmacokinetics/pharmacodynamics, dosing recommendations, drug interactions, other potential indications, and ongoing clinical trials.

Keywords: IL-23 inhibitor; biologics; efficacy; plaque psoriasis; risankizumab; safety.

PubMed Disclaimer

Conflict of interest statement

WL is funded in part by a grant from the National Institutes of Health (U01AI119125) and National Psoriasis Foundation, and has received research funding from Abbvie, Amgen, Janssen, Novartis, Pfizer, Regeneron, and Trex Bio. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Week 16 PASI 90 and sPGA 0/1 Reponse Rates in UltIMMA-1 and UltIMMA-2. Data from Gordon et al.
Figure 2
Figure 2
Week 52 PASI 90 and sPGA 0/1 Reponse Rates in UltIMMA-1 and UltIMMA-2. Data from Gordon et al.
Figure 3
Figure 3
Week 16 PASI 90 and SPGA 0/1 Response Rate in IMMvent. Data from Reich et al.
Figure 4
Figure 4
Week 44 PASI 90 and SPGA 0/1 Response Rate in Re-randomized Subjects in IMMvent. Data from Reich et al.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70(3):512–516. doi:10.1016/j.jaad.2013.11.013 - DOI - PubMed
    1. Alinaghi F, Calov M, Kristensen LE, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251–265.e19. doi:10.1016/j.jaad.2018.06.027 - DOI - PubMed
    1. Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol. 2017;76(3):377–390. doi:10.1016/j.jaad.2016.07.064 - DOI - PMC - PubMed
    1. Singh P, Silverberg JI. Under-screening of depression in United States outpatients with atopic dermatitis and psoriasis. Br J Dermatol. 2019. doi:10.1111/bjd.18629 - DOI - PubMed
    1. Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017;140(3):645–653. doi:10.1016/j.jaci.2017.07.004 - DOI - PMC - PubMed